Spirulina
Spirulina scored 7.6 / 10 (💪 Strong recommend) on the BioHarmony scale as a Whole-food supplement (dried blue-green algae biomass, Arthrospira).
Spirulina is dried Arthrospira blue-green algae with real human meta-analytic support: pooled randomized trials show systolic blood pressure falling about 4.6 mmHg and diastolic about 7 mmHg per Machowiec 2021, plus meaningful drops in LDL, triglycerides, and fasting glucose. It is cheap and very safe when sourced clean. The main caveat is microcystin contamination from uncertified producers.
What is Spirulina?
Spirulina is dried blue-green algae, specifically the cyanobacteria Arthrospira platensis and Arthrospira maxima, sold as a deep green powder or pressed tablets and used as both a food and a supplement. It is one of the few cheap supplements with a genuine human-trial record: pooled randomized trials in Machowiec 2021 show systolic blood pressure falling about 4.59 mmHg and diastolic about 7.02 mmHg, and separate meta-analyses show meaningful drops in LDL, triglycerides, and fasting glucose. That cardiometabolic cluster, combined with a benign safety profile and a per-month cost in the $10 to $25 range, is why it lands in strong-recommend territory and sits comfortably above the heavily marketed GLP-1 drugs on a cost-adjusted basis.
What you are actually taking is nutrient-dense biomass. Spirulina is roughly 60 to 70 percent protein by dry weight and carries phycocyanin, gamma-linolenic acid, carotenoids, chlorophyll, B vitamins, and iron. The phycocyanin pigment drives much of the antioxidant and anti-inflammatory activity studied in the lab. The honest framing is that spirulina behaves like a concentrated food that nudges several risk markers at once, not like a single-target drug, and the magnitude of each individual effect is modest. The one thing that can turn a benign food into a real hazard is sourcing, since open-pond product from uncertified producers can pick up microcystin toxins or heavy metals.
Terminology
The terms that matter most for spirulina are the ones that separate the safe, well-studied food from the marketing halo and from the real contamination risk. Knowing that Arthrospira is the actual organism, that microcystins are an extrinsic contamination problem and not something the algae makes, and that most clinical benefit is cardiometabolic will keep you from over-claiming and from buying a risky product.
- Arthrospira: The genus of the cyanobacteria sold as spirulina, mainly Arthrospira platensis and Arthrospira maxima. The marketing name spirulina is older than the current taxonomy.
- Cyanobacteria: Photosynthetic bacteria, historically called blue-green algae. Spirulina is technically a bacterium, not a plant.
- Phycocyanin: The blue pigment-protein in spirulina that carries most of its antioxidant and anti-inflammatory activity.
- GLA: Gamma-Linolenic Acid, an omega-6 fatty acid present in spirulina and linked to anti-inflammatory signaling.
- Microcystins: Liver-toxic compounds made by certain contaminant cyanobacteria. They are a sourcing problem in open-pond product, not a product of Arthrospira itself.
- PKU: Phenylketonuria, a metabolic disorder in which phenylalanine cannot be processed. Spirulina contains phenylalanine and is contraindicated.
- NAFLD: Non-Alcoholic Fatty Liver Disease, a target of some spirulina trials measuring liver enzymes.
- CRP: C-Reactive Protein, a blood marker of inflammation that fell modestly in pooled trials.
- HbA1c: Glycated hemoglobin, a three-month average of blood sugar. Spirulina moves fasting glucose more reliably than HbA1c.
- SMD: Standardized Mean Difference, an effect-size metric used in meta-analyses.
- WMD: Weighted Mean Difference, a pooled effect expressed in the original units such as mmHg.
- COA: Certificate of Analysis, the lab document that verifies a product's identity, potency, and contaminant levels.
How do you take Spirulina?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral powder | Loose dried algae powder | 1 to 8 g/day | 1 to 10 g/day |
| Oral tablet | Compressed tablets, typically 500 mg each | 1 to 8 g/day | 1 to 10 g/day |
Protocols
Blood pressure and lipid support Clinical
- Dose
- 1 to 4.5 g/day
- Frequency
- Daily
- Duration
- 12 weeks minimum to judge effect
Matches the dose range used in the blood-pressure and lipid meta-analyses. Track blood pressure and a lipid panel before and after.
Glycemic and metabolic support Clinical
- Dose
- 2 to 8 g/day
- Frequency
- Daily
- Duration
- 8 to 12 weeks
Glycemic and NAFLD trials cluster in this range. Pair with a fasting glucose check, since the pooled effect is on fasting glucose more than HbA1c.
How this score is calculated →
What are the benefits of Spirulina?
Upside contribution: 2.48
| Dimension | Weight | Band | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | Strong | 0.900 | |
| Breadth | 15% | Strong | 0.555 | |
| Evidence | 25% | Strong | 0.975 | |
| Speed | 10% | Limited | 0.230 | |
| Durability | 10% | Limited | 0.220 | |
| Bioindividuality | 15% | Strong | 0.600 | |
| Total | 3.480 | |||
| Baseline offset (constant) | −1.000 | |||
| Effective upside contribution | 2.480 |
Dimensions are shown as a band rather than a decimal because repeat scoring of the same evidence moves a single dimension by up to 1 point. Hover or long-press a band to see the value it was scored at.
Upside Rationale
The upside comes from one strong, replicated cluster: cardiometabolic risk factors. The single most citable finding comes from Machowiec 2021, a meta-analysis of randomized trials showing systolic blood pressure down 4.59 mmHg and diastolic down 7.02 mmHg, with the largest effect in people who started hypertensive. Around that sit consistent lipid and glucose meta-analyses. The key boundary condition is that each effect is modest and most sit on surrogate markers, so spirulina is a coherent adjunct to diet, exercise, and medication, not a standalone therapy. The breadth of small simultaneous benefits, the food-grade safety, and the very low cost are what carry the score.
Efficacy (Strong): Spirulina reaches the low end of the SM-032 moderate-to-large band on replicated pooled magnitudes rather than a single trial. Rahnama 2023, the largest lipid pool at 20 studies and 1,076 participants, reports LDL, total cholesterol and triglycerides each falling by a standardized mean difference of 0.6, which sits in the moderate-to-large effect range. Hatami 2021 pooled 8 studies with fasting glucose down 17.88 mg/dL, and Machowiec 2021 found systolic pressure down 4.59 and diastolic down 7.02 mmHg. Spirulina stays out of the top band because these are surrogate markers, individual trials are small, and Lak 2025 caps body composition near one kilogram.
Breadth of benefits (Strong): Spirulina touches several systems with at least one human endpoint each, the several-validated-lanes-with-thinner-edges band. Cardiovascular rests on Machowiec 2021 and Shiri 2025, lipids on Rahnama 2023 and Serban 2016, glycemia on Hatami 2021 and the independent Ghanbari 2022 pool, body composition on Lak 2025 at 1.07 kg and Zarezadeh 2021, and inflammation on Shahraki Jazinaki 2025 with CRP down 0.55 mg/L. The edges are genuinely thin: allergic rhinitis rests on the single unreplicated Cingi 2008 trial and exercise on Kalafati 2010 with nine participants and Lu 2006 with sixteen. Cognition, mood and hormonal claims have no human support.
Evidence quality (Strong): Spirulina earns the upper solid-signal band of SM-050 because independent teams keep reproducing the same direction: two blood-pressure meta-analyses including the GRADE-assessed Shiri 2025, three lipid pools including the GRADE-assessed Rahnama 2023 across 23 arms, two glycaemic pools in Hatami 2021 and Ghanbari 2022 that agree fasting glucose moves and glycated haemoglobin does not, and two body-composition pools. SM-051a is satisfied on the traditional leg too, because the food record is cited rather than asserted, through Ciferri 1983, Metcalf 2021 on Lake Chad Dihe and Soudy 2018 measuring higher serum retinol in daily eaters. Small short trials, industry-adjacent inclusions, the null Mohiti 2021 and the Mazloomi 2022 expression of concern block the top band.
Speed of onset (Limited): Spirulina is among the slower interventions in the catalog, sitting in the weeks-to-months band that the SM-066 ladder gives C15, resveratrol and urolithin A. The packet is explicit that spirulina has no acute effect to feel on day one. The blood-pressure and lipid trials establishing the evidence ran roughly 6 to 12 weeks, the glycemic and liver trials 8 to 12 weeks, and Cingi 2008 reported allergic rhinitis relief building over several weeks of daily use. The packet sets first noticeable effect at 6 weeks and the practical benchmark at a 12-week commitment with before-and-after measurement.
Durability (Limited): Spirulina belongs in the band where the benefit requires continued use and disappears within days to months of stopping. The packet states directly that the cardiometabolic effects of spirulina depend on continued daily dosing and that there is no evidence of any lasting benefit after stopping, with markers drifting back toward baseline exactly as most dietary changes do. Spirulina sits mid-band rather than at the floor because the markers themselves move on a slow 6-to-12-week timescale, so the drift back is gradual rather than immediate. No structural change, learned skill or resolved condition is attributed to spirulina anywhere.
Bioindividuality (Strong): Spirulina response is unusually predictable in advance, which is the clear-majority-respond band at its top. Machowiec 2021 found the blood-pressure effect concentrated in the hypertensive subgroup, and Shiri 2025 independently found larger effects in hypertensive and overweight participants. The same baseline-dependence holds for LDL, triglycerides and fasting glucose: elevated markers move, optimal markers have no room. That makes spirulina trivially targetable, because the predictor is a blood-pressure cuff or an ordinary lipid and glucose panel rather than a genotype or a specialist test. Spirulina falls short of the top band only because response magnitude within the elevated group still varies.
What are the risks & downsides of Spirulina?
Downside contribution: 0.38 (safety risks weighted extra)
| Dimension | Weight | Band | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | Negligible | 0.420 | |
| Side effects | 15% | Low | 0.225 | |
| Cost premium | 5% | Low | 0.075 | |
| Effort | 5% | Negligible | 0.065 | |
| Opportunity | 5% | Low | 0.115 | |
| Dependency | 15% | Negligible | 0.150 | |
| Reversibility | 25% | Negligible | 0.250 | |
| Total | 1.300 | |||
| Harm subtotal × 1.4 | 1.463 | |||
| Opportunity subtotal × 1.0 | 0.255 | |||
| Combined downside | 1.718 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.378 |
Dimensions are shown as a band rather than a decimal because repeat scoring of the same evidence moves a single dimension by up to 1 point. Hover or long-press a band to see the value it was scored at.
Cost premium: premium over the cheapest legitimate route, not price.
Downside Rationale
The dominant concern with spirulina is not intrinsic toxicity but sourcing. The algae itself is a benign food with a centuries-long use history, so the harm dimensions score low. The people most exposed are those who buy uncertified open-pond product that can carry microcystin toxins or heavy metals, plus the narrow groups with a real intrinsic contraindication: anyone with phenylketonuria and, more cautiously, people with autoimmune disease. Everything else is mild and reversible. Per the spec, the contamination risk is treated as an extrinsic sourcing caveat surfaced in the Verdict and confidence label, not as an inflation of the intrinsic Safety score.
Safety (Negligible): Clean-sourced spirulina belongs in the benign floor band, where every alarming signal reclassifies as extrinsic sourcing or a narrow contraindicated population. That is literally the case here. Microcystin and heavy-metal findings in Rhoades 2023 come from contaminant cyanobacteria in open-pond production, not from Arthrospira, and Pinchart 2023 found over 99 percent of 623 monitored batches below the 1 ppm limit, so SM-054 and SM-055 route contamination to the sourcing caveat. Phenylketonuria is a hard contraindication in a screened population, excluded by SM-024, and the autoimmune flare concern is theoretical, which SM-060 declines to penalize.
Side effects (Low): Spirulina causes mild, infrequent, dose-manageable complaints, which is the rare-or-mild band. The packet names transient GI upset, mild nausea, bloating or loose stools when starting or at higher doses, usually settling within days, plus dislike of the powder's strong taste and smell. No consistent pattern of serious side effects appears in the randomized trials behind Machowiec 2021, Rahnama 2023 or Hatami 2021, and what does occur is dose-related and reversible, largely avoided by starting low and building up over a week. Contamination-driven harm is extrinsic under SM-055 and belongs to sourcing, not here.
Cost premium (Low): Spirulina costs roughly 10 to 25 dollars a month at 3 to 5 grams a day for reputable third-party-tested powder or tablets, which sits at the very bottom of the ordinary-ongoing-cost band of the SM-066 ladder. SM-007a scores the premium over the cheapest legitimate route, and for spirulina there is no cheaper equivalent route to the same exposure: spirulina is already the commodity, powder is cheaper per gram than tablets, and the packet reports no meaningful brand-versus-generic premium beyond verified quality. The only spend-up worth making, third-party certification, is what separates a benign food from a contamination risk.
Effort (Negligible): Spirulina sits just above the under-a-minute-a-day floor. The protocol is a single daily dose with no cycling, no timing rule, no fasting window and no requirement to take it with food, and tablets make the dose countable. Two small frictions keep spirulina off the absolute floor. The powder's strong taste and smell means most users blend it into something, which is a daily preparation step rather than swallowing a capsule. Sourcing requires reading a current certificate of analysis once. Marker tracking is optional and periodic, so it does not lift spirulina into the few-minutes-a-day band.
Opportunity cost (Low): Spirulina sits in the band where a concrete better-evidenced alternative exists in the same category. For every marker spirulina moves there is a stronger validated lever: antihypertensive therapy and sodium and weight change for blood pressure, statins for LDL, and diet and activity for fasting glucose, all with larger effects than the several-mmHg and modest-lipid magnitudes spirulina delivers. The packet names the displacement risk directly, that the small per-marker effects can create a false sense the cardiometabolic problem is handled. Spirulina does not interfere with exercise and stacks cleanly with medications, so nothing shows it blunting a better lever.
Dependency (Negligible): Spirulina sits at the floor of the dependency ladder with no qualification. The packet reports no dependency, no tolerance and no withdrawal syndrome, and states plainly that spirulina is a food and that stopping it produces no physiological withdrawal. The ladder is explicit that the only thing reversing on discontinuation, the cardiometabolic markers drifting back toward baseline, is a Durability point and never a dependency one, and the packet itself makes that same distinction. No craving, no dose escalation and no psychological pull is named for spirulina anywhere in the evidence pool or the prose.
Reversibility (Negligible): Spirulina clears with no named durable-harm carve-out, the top band of the corrected SM-067 reversibility ladder. The packet states that stopping spirulina is clean and immediate, requires no taper, and leaves no lasting changes, because spirulina is a dietary intervention with a short biological footprint. No permanent physiological change is attributable to the algae itself. Per SM-046 the fading of the cardiometabolic benefit is scored in Durability rather than here, and the microcystin contamination question, which is the only route to a durable harm, is extrinsic under SM-055 and routed to the sourcing caveat.
Is Spirulina worth it?
Spirulina earns Strong recommend at 7.5–8.0/10 because it delivers a replicated cluster of cardiometabolic benefits at food-grade safety and an unusually low cost. The practical verdict: if you have elevated blood pressure, lipids, or fasting glucose, a certified spirulina product is a cheap, low-risk add-on worth a measured 12-week trial. If your markers are already optimal, expect little, and if you have phenylketonuria or active autoimmune disease, it is not for you. The score tier is justified by the breadth of meta-analytic support and the benign risk profile, tempered to moderate confidence because individual trials are small and antioxidant outcomes are mixed. The sourcing caveat is the whole game: the algae is safe, but uncertified product is not.
✅ Best for: People with elevated blood pressure who want a cheap evidence-backed adjunct, given the several-mmHg pooled effect in Machowiec 2021; people with high LDL or triglycerides looking for a food-grade lipid nudge; people with prediabetes or type 2 diabetes targeting fasting glucose specifically; cost-conscious supplement users who want a dense nutrient base of protein, iron, and carotenoids; allergic rhinitis sufferers willing to run a personal trial after Cingi 2008; and measurement-minded people who will pick one marker, dose for 12 weeks, and re-test.
❌ Avoid if: You have phenylketonuria, since spirulina contains phenylalanine and is contraindicated; you have active autoimmune disease such as lupus or rheumatoid arthritis, where immune stimulation could theoretically trigger a flare; you are pregnant or breastfeeding without clinician guidance; or you cannot verify your product. The contamination findings in Rhoades 2023 mean uncertified open-pond product can carry microcystins or heavy metals, so a current certificate of analysis showing microcystins below 1 ppm is mandatory, especially for children.
What is Spirulina best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Cardiovascular: 7.5/10
Score: 7.5/10The blood-pressure signal is real and replicated. Machowiec 2021 pooled 5 randomized trials in 230 subjects and found systolic pressure falling 4.59 mmHg and diastolic falling 7.02 mmHg, with the largest effect in people who started hypertensive. Shiri 2025, a GRADE-assessed meta-analysis, confirmed the direction with systolic down 4.41 mmHg and diastolic down 2.84 mmHg. Combined with consistent lipid improvement, this is a coherent cardiometabolic effect at a few grams a day. It is an adjunct to diet, exercise, and medication when indicated, not a replacement, but the magnitude is clinically meaningful for a cheap food.
Metabolic Health: 7.0/10
Score: 7.0/10Spirulina improves several risk factors at once. Huang 2018 pooled 12 trials and reported fasting glucose down 5.01 mg/dL, triglycerides down 39.2 mg/dL, and diastolic pressure down 7.17 mmHg. The lipid and blood-pressure meta-analyses point the same way. This clustering of small benefits across glucose, lipids, and pressure is exactly what makes it useful for someone with early metabolic syndrome. The honest boundary is that each individual effect is modest, and these are surrogate markers, so pair it with the lifestyle work that drives the bulk of metabolic improvement.
Blood Sugar / Glycemic Control: 7.0/10
Score: 7.0/10Hatami 2021 pooled 8 studies in type 2 diabetes and found fasting glucose dropping 17.88 mg/dL, although HbA1c did not move significantly. Ghanbari 2022 similarly found a significant fasting-glucose reduction with a non-significant HbA1c change. The takeaway is honest: spirulina nudges fasting glucose more reliably than it shifts longer-term HbA1c, so it suits someone targeting fasting numbers as one lever among diet, weight, and activity rather than as a standalone diabetes therapy.
Respiratory: 6.5/10
Score: 6.5/10Cingi 2008 ran a double-blind placebo-controlled trial in allergic rhinitis and found spirulina significantly improving nasal discharge, sneezing, congestion, and itching versus placebo. That is a real, symptom-level outcome rather than a biomarker, which is why it lifts this subrating despite resting on one trial. The boundary is replication: one well-designed RCT is encouraging but not the same as a meta-analytic body, so treat allergic rhinitis as a promising off-core use worth a personal trial.
Body Composition / Fat Loss: 6.0/10
Score: 6.0/10The anthropometric meta-analyses are consistent but small in magnitude. Zarezadeh 2021 found body weight down 1.85 kg and waist circumference down 1.09 cm, with BMI moving only in trials lasting 12 weeks or more. Lak 2025, a GRADE-assessed dose-response meta-analysis of 17 RCTs, reported body weight down 1.07 kg, BMI down 0.40, and body fat down 0.84 percent. These are genuine pooled effects but a kilogram or two is a supporting role, useful alongside a calorie and training plan rather than as a fat-loss driver.
Anti-Inflammatory: 6.0/10
Score: 6.0/10The inflammation evidence is real but smaller than the cardiometabolic case. Shahraki Jazinaki 2025 pooled 7 trials in 283 subjects and found C-reactive protein falling 0.55 mg/L, a significant result. Mohiti 2021, however, found pooled malondialdehyde and IL-6 reductions that trended down but did not reach significance. So the CRP signal supports a moderate score while the oxidative-stress markers temper enthusiasm. Spirulina is a reasonable adjunct for someone tracking CRP, not a proven anti-inflammatory for harder endpoints.
Liver / Detoxification: 5.5/10
Score: 5.5/10The NAFLD signal is suggestive but thin. Mazloomi 2022 ran a randomized double-blind trial in 46 NAFLD patients using 20 g/day for 8 weeks and reported significant between-group improvement in ALT, AST, malondialdehyde, and total antioxidant capacity. That trial later received an Expression of Concern, so it is cited with that flag and not leaned on heavily. The honest read is that liver enzymes plausibly improve alongside the broader metabolic effect, but the dedicated human evidence is one flagged trial, so keep expectations modest.
Immune Function: 5.0/10
Score: 5.0/10The human evidence is indirect. Spirulina phycocyanin has antioxidant and immunomodulatory activity in mechanistic and animal work, and the Cingi 2008 allergic rhinitis RCT is the closest human immune-related outcome. There is no strong human trial base for infection resistance or vaccine response specific to spirulina. The score reflects plausible biology plus one allergy RCT, balanced against the autoimmune-flare caution that means immune modulation can cut both ways for the wrong person.
Energy / Fatigue: 5.0/10
Score: 5.0/10Kalafati 2010 used a double-blind crossover in 9 trained men at 6 g/day for 4 weeks and found time to fatigue rising from 2.05 to 2.70 minutes with a 10.9 percent rise in fat oxidation. Lu 2006 reported extended time to exhaustion and lower exercise-induced oxidative damage. These are small, short studies in athletes, so the signal is real but modest and not yet a robust fatigue claim for the general user.
Endurance / Cardio: 5.0/10
Score: 5.0/10Kalafati 2010 found a meaningful rise in time to fatigue and fat oxidation in trained men, and Lu 2006 extended time to exhaustion while lowering oxidative-stress markers. Both are small double-blind trials, which is encouraging, but the total participant count is low and replication in larger or recreational populations is missing. Treat the ergogenic effect as a plausible bonus rather than a primary reason to supplement.
Antioxidant / Oxidative Stress: 5.0/10
Score: 5.0/10The pooled human data is mixed. Mohiti 2021 pooled 11 trials in 465 participants and found malondialdehyde reduction that did not reach significance, with IL-6 and TBARS trending down but non-significant. Individual exercise trials like Lu 2006 show lower oxidative markers, but the meta-analytic picture is inconsistent. Phycocyanin is a genuine antioxidant in vitro, yet the human outcome data does not yet justify a confident antioxidant claim, which keeps this at a middling score.
| Use Case | Score | Summary |
|---|---|---|
| ○ Healthspan | 4.5 | The cluster of blood-pressure, lipid, and glucose improvements supports a modest healthspan case, but it rests on surrogate markers rather than functional aging endpoints. |
| ○ Geriatric / Aging Population | 4.5 | Plausible for older adults given the cardiometabolic effects and complete protein, but dedicated trials in geriatric populations are sparse; sourcing caution matters more in vulnerable groups. |
| ○ Longevity / Lifespan | 4.0 | Indirect only. Cardiometabolic risk-factor improvement is consistent with healthier aging, but there are no human lifespan or hard-outcome trials for spirulina. |
| ○ Recovery / Repair | 4.0 | Lower exercise-induced oxidative damage in small trials like Lu 2006 suggests mild recovery support, but dedicated recovery endpoints are limited. |
| ○ Gut Health / Microbiome | 3.5 | Prebiotic and microbiome effects are mostly preclinical; human gut-outcome trials specific to spirulina are limited. |
| ○ Heavy Metal / Toxin Burden | 3.0 | Often marketed for detox, but human chelation evidence is weak. The bigger issue is that uncertified spirulina can itself carry heavy metals, so the detox framing is the opposite of reassuring. |
| ○ Kidney Function | 3.0 | Some animal nephroprotection data exists, but direct human renal-outcome evidence is lacking. |
| ○ Cognition / Focus | 3.0 | No meaningful human cognition trials for spirulina; any benefit would be indirect via metabolic and vascular health. |
| ○ Mood / Emotional Regulation | 3.0 | No direct mood or depression RCT base; mechanistic links through inflammation are speculative for this compound. |
| ○ Skin / Beauty | 3.0 | Carotenoid and antioxidant content gives a plausible skin rationale, but human skin-outcome trials are minimal. |
Compare Spirulina with
Frequently Asked Questions
What does spirulina actually do in the body?
Spirulina is dried Arthrospira algae packed with phycocyanin, gamma-linolenic acid, carotenoids, chlorophyll, and complete protein, and in humans it produces modest reductions in blood pressure, LDL, triglycerides, and fasting glucose. Machowiec 2021 pooled randomized trials showing systolic pressure down 4.59 mmHg and diastolic down 7.02 mmHg. Think of it as a nutrient-dense food that nudges several cardiometabolic markers, not a single-target drug.
How much spirulina should I take and when?
Most clinical benefit shows up at 1 to 8 g/day, with blood-pressure and lipid trials clustering at 1 to 4.5 g/day and glycemic or liver trials at 2 to 8 g/day. Timing is flexible; take it daily with or without food. Powder is cheapest but strong-tasting, while tablets let you count the dose. Give any target at least 8 to 12 weeks before judging, and track the relevant marker.
What does the human evidence on spirulina actually show?
The strongest human evidence is cardiometabolic. Meta-analyses show blood pressure falling several mmHg per Machowiec 2021, LDL down about 41 mg/dL and triglycerides down about 44 mg/dL per Serban 2016, and fasting glucose down about 18 mg/dL in type 2 diabetes per Hatami 2021. Allergy and exercise have single supportive RCTs. Antioxidant and inflammation results are mixed.
Is spirulina safe to take long-term?
Clean-sourced spirulina has a benign safety profile, with mild GI upset as the most common complaint, and it has a centuries-long food-use history. The real risk is extrinsic: open-pond product from uncertified producers can carry microcystins or heavy metals, as Rhoades 2023 documented in retail samples. The algae itself does not make those toxins. Buy from a producer with a current certificate of analysis.
Who should avoid spirulina?
Anyone with phenylketonuria should avoid spirulina because it contains phenylalanine. People with autoimmune conditions like lupus or rheumatoid arthritis should be cautious, since spirulina can stimulate immune activity and a theoretical flare cannot be ruled out. Pregnant or breastfeeding people should use it only under clinician guidance, and children need certified product given the contamination findings in Rhoades 2023.
Spirulina vs chlorella: which one should I choose?
Spirulina has the stronger human evidence base for cardiometabolic outcomes, with multiple meta-analyses on blood pressure, lipids, and glucose, while chlorella's human trials are fewer and more heterogeneous. Chlorella is promoted more for heavy-metal binding, though that evidence is weaker. If your goal is measurable blood-pressure, lipid, or glucose support, spirulina is the better-evidenced pick. Both share the same sourcing caution around contamination.
How fast does spirulina start working?
Plan on weeks, not days. The blood-pressure and lipid trials that establish the evidence ran roughly 6 to 12 weeks, and glycemic and liver trials used 8 to 12 weeks. Allergic rhinitis symptom relief in Cingi 2008 emerged over several weeks of daily use. There is no acute effect to feel on day one, so commit to a 12-week run and measure the marker you care about before and after.
How do I know my spirulina is not contaminated?
Demand a current certificate of analysis showing microcystins below 1 ppm and heavy metals within limits. Pinchart 2023 found over 99 percent of monitored production batches below the 1 ppm microcystin limit, but Rhoades 2023 found measurable microcystins in all five retail products tested. The toxins come from contaminant cyanobacteria in open ponds, not from Arthrospira itself, so producer quality control is everything.
What could change Spirulina's score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
The most plausible upward move would come from large, long, independent randomized trials confirming the cardiometabolic effects on hard endpoints rather than surrogate markers, which would lift Efficacy and Evidence first. The most plausible downward move would be a documented intrinsic safety signal from clean product or evidence that the contamination problem is more widespread than current monitoring suggests, which would pull Safety and confidence. Because the current case rests on consistent meta-analytic direction with modest magnitudes, the score is more likely to firm up than to swing hard in either direction.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| Large independent RCT confirms blood-pressure and lipid effects on hard endpoints | Efficacy 3.3 to 3.9, Evidence 3.4 to 4.0 | 7.8 / 10 💪 Strong recommend |
| Industry-funding adjustment confirmed across the lipid and BP trial pool | Evidence 3.4 to 3.0 | 7.3 / 10 💪 Strong recommend |
| Contamination shown to be widespread and hard to verify even in certified product | Safety 1.6 to 2.6, confidence to Low | 6.3 / 10 👍 Worth trying |
| Allergic rhinitis effect replicated in a second well-designed RCT | Breadth 3.7 to 3.9 | 7.7 / 10 💪 Strong recommend |
| Antioxidant and inflammation outcomes confirmed in newer meta-analyses | Breadth 3.7 to 4.0, Efficacy 3.3 to 3.5 | 7.7 / 10 💪 Strong recommend |
| A demonstrated intrinsic safety signal emerges from clean-sourced product | Safety 1.6 to 3.0, Side effects 1.6 to 2.2 | 6.6 / 10 👍 Worth trying |
Key Evidence Sources
- Machowiec 2021, Nutrients: meta-analysis of 5 randomized controlled trials (230 subjects) on spirulina and blood pressure. Systolic blood pressure fell 4.59 mmHg (95% CI -8.20 to -0.99) and diastolic fell 7.02 mmHg (95% CI -8.86 to -5.18), with the effect concentrated in the hypertensive subgroup. Doses 1 to 8 g/day, 2 to 12 weeks.
- Shiri 2025, Phytotherapy Research: GRADE-assessed systematic review and meta-analysis of spirulina and blood pressure in adults. Independent confirmation of the blood-pressure direction. Systolic down 4.41 mmHg (95% CI -6.74 to -2.07) and diastolic down 2.84 mmHg (95% CI -4.65 to -1.03), moderate certainty under GRADE, with larger effects in hypertensive and overweight people and trials longer than 8 weeks.
- Serban 2016, Clinical Nutrition: meta-analysis of 7 randomized controlled trials on spirulina and plasma lipids. LDL cholesterol down 41.32 mg/dL (95% CI -60.62 to -22.03), triglycerides down 44.23 mg/dL (95% CI -50.22 to -38.24), total cholesterol down 46.76 mg/dL, HDL up 6.06 mg/dL. Effects were independent of dose and grew with duration.
- Rahnama 2023, Pharmacological Research: GRADE-assessed dose-response meta-analysis of 20 studies (23 arms, 1,076 participants) on spirulina and lipid profile. The largest lipid pool. LDL, total cholesterol and triglycerides each fell by a standardized mean difference of -0.6 (95% CI -0.9 to -0.2) and HDL rose 0.3 (95% CI 0.0 to 0.6). Confirms the direction of the older Serban pool on four times as many trials.
- Hatami 2021, Journal of Diabetes and Metabolic Disorders: meta-analysis of 8 studies of spirulina in type 2 diabetes. Fasting blood glucose fell 17.88 mg/dL (95% CI -26.99 to -8.78), triglycerides 30.99 mg/dL, total cholesterol 18.47 mg/dL and LDL 20.04 mg/dL. No significant effect on HbA1c or post-prandial glucose, which is the boundary condition on the glycemic claim.
- Ghanbari 2022, Current Problems in Cardiology: systematic review and meta-analysis of 7 clinical and 27 preclinical Arthrospira studies on glycemic control. Second independent glycemic pool. Fasting blood sugar fell significantly, along with total cholesterol and triglycerides, and HDL rose, while HbA1c did not move significantly. Replicates the fasting-glucose-but-not-HbA1c pattern seen in Hatami 2021.
- Huang 2018, Diabetes Metabolic Syndrome and Obesity: meta-analysis of 12 trials (14 arms) on spirulina, lipids, glucose, body weight and blood pressure. Total cholesterol down 36.60 mg/dL, LDL down 33.16 mg/dL, triglycerides down 39.20 mg/dL, fasting glucose down 5.01 mg/dL and diastolic blood pressure down 7.17 mmHg. Doses ranged 1 to 19 g/day over 2 to 48 weeks, and the results survived sensitivity analysis with no obvious publication bias.
- Shahraki Jazinaki 2025, Food Science and Nutrition: dose-response meta-analysis of 7 trials (283 subjects) on spirulina and C-reactive protein. CRP fell 0.55 mg/L (95% CI -0.90 to -0.21, p = 0.002), with high heterogeneity (I2 = 86.7%) and no significant dose or duration relationship. This is the anchor for the inflammation claim and the reason it is scored moderately rather than strongly.
- Mohiti 2021, Clinical and Experimental Pharmacology and Physiology: meta-analysis of 11 trials (465 subjects) on spirulina, oxidative stress and pro-inflammatory biomarkers. The negative result that caps the antioxidant score. No significant effect on TNF-alpha or malondialdehyde; IL-6 and TBARS trended down without reaching significance; an IL-2 increase became non-significant on sensitivity analysis. Cited to temper the antioxidant marketing claim, not to support it.
- Lak 2025, Nutrition and Metabolism: GRADE-assessed dose-response meta-analysis of 17 randomized controlled trials on spirulina and body composition. Body weight down 1.07 kg (p = 0.004), BMI down 0.40 (p = 0.025), body fat percentage down 0.84 (p = 0.002), waist circumference unchanged. A dose-response effect on BMI was significant. Sets the honest ceiling on the body-composition claim at about a kilogram.
- Zarezadeh 2021, Phytotherapy Research: meta-analysis of controlled clinical trials on spirulina and anthropometric indices. Body weight down 1.85 kg (95% CI -2.44 to -1.26) and waist circumference down 1.09 cm (95% CI -2.16 to -0.01). BMI moved only in trials lasting at least 12 weeks, which is where the 12-week trial recommendation comes from.
- Cingi 2008, European Archives of Oto-Rhino-Laryngology: double-blind placebo-controlled trial of spirulina in allergic rhinitis. Spirulina significantly improved nasal discharge, sneezing, nasal congestion and itching versus placebo (p below 0.001). A symptom-level rather than biomarker outcome, but a single unreplicated trial, which is why allergy is scored as promising rather than established.
- Kalafati 2010, Medicine and Science in Sports and Exercise: double-blind placebo-controlled crossover trial of 6 g/day spirulina for 4 weeks in 9 trained men. Time to fatigue after a 2-hour run rose from 2.05 to 2.70 minutes, carbohydrate oxidation fell 10.3% and fat oxidation rose 10.9%. Glutathione was higher and post-exercise TBARS did not rise on spirulina. Nine participants, so the ergogenic signal is real but small.
- Lu 2006, European Journal of Applied Physiology: trial of Spirulina platensis and exercise-induced skeletal muscle damage in 16 untrained students. Malondialdehyde fell and superoxide dismutase rose after supplementation, and time to exhaustion on a Bruce treadmill protocol was significantly extended. Small and short, and the second of only two exercise trials behind the energy and endurance subratings.
- Mazloomi 2022, Food Science and Nutrition: randomized double-blind trial of 20 g/day spirulina sauce for 8 weeks in 46 NAFLD patients. Fatty liver grade, ALT (p = 0.03), AST (p = 0.02), malondialdehyde (p = 0.04) and total antioxidant capacity (p below 0.001) improved between groups. Carries a 2025 Expression of Concern in Food Science and Nutrition, so it is cited with that flag and the liver subrating is capped at 5.5.
- Rhoades 2023, Microorganisms: microbiota and cyanotoxin analysis of 5 retail spirulina supplements and spirulina-supplemented foods. Microcystins were detected in all five products, and estimated daily intake from the spirulina powder and tablets exceeded the tolerable daily intake set for infants (200 ng) and children (800 ng). Potentially pathogenic bacteria including Bacillus cereus and Klebsiella pneumoniae were also found. This is the source of the sourcing caveat.
- Pinchart 2023, Toxins: microcystin surveillance of 623 dry spirulina samples from 95 French small-scale producers, 2013 to 2021. More than 99% of results were below the 1 ppm regulatory limit and the period average was 0.21 ppm, with none of the 623 samples exceeding it. Also documents where the 1 ppm limit comes from: the Oregon Department of Agriculture in 1997, derived from the WHO tolerable daily intake for microcystin-LR. The counterweight to Rhoades 2023: quality-controlled production is clean.
- Karkos 2010, Evidence-Based Complementary and Alternative Medicine: review of evidence-based human applications of spirulina in clinical practice. Source for the food-use history and the composition claim. States that spirulina has a long history of use as food with reported use during the Aztec civilization, and that it is up to 70% protein by dry weight alongside B vitamins and provitamin A. Epub October 2010, collection volume 2011.
- Ciferri 1983, Microbiological Reviews: Spirulina, the edible microorganism. The canonical review establishing spirulina as a documented human foodstuff rather than a modern supplement invention, and the standard reference for its traditional harvest and consumption.
- Metcalf 2021, Neurotoxicity Research: cyanotoxin and amino acid analysis of Dihe, the traditional Arthrospira food of Lake Chad. Documents the living tradition directly: Arthrospira fusiformis is collected from Lake Chad, dried into thin wafers called Dihe, and sold in local markets. BMAA was not detected. Microcystins were present in 6 market samples at up to 20 micrograms per gram, which is the same extrinsic sourcing problem seen in retail supplements.
- Soudy 2018, PLOS ONE: observational study of vitamin A status in 88 women eating traditionally prepared spirulina (Dihe) around Lake Chad. Confirms daily traditional consumption of Dihe as an ordinary food in the Lake Chad region and shows a measurable nutritional consequence: women eating it had higher serum retinol (1.26 vs 1.03 micromol/L, p = 0.008) and 77% versus 29% had adequate retinol status.
What does the evidence say about Spirulina?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Machowiec 2021, Shiri 2025, Serban 2016, Rahnama 2023, Hatami 2021, Huang 2018, Shahraki Jazinaki 2025, Mohiti 2021
Traditional Medicine Systems
Confidence: Medium
Citations: Karkos 2010, Ciferri 1983, Metcalf 2021, Soudy 2018
Holistic Evidence for Spirulina
Centuries of safe food use across two cultures converge with modern randomized-trial evidence that spirulina modestly improves blood pressure, lipids, and fasting glucose, which together support a strong-recommend score for a cheap, low-risk whole food.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- LDL Cholesterol Pre | Expected Down
- Triglycerides During | Expected Down
- Fasting Glucose Pre | Expected Down
- ALT During | Expected Down
Pulse Dimensions to Watch
- Energy During | Expected Watch | Secondary
- Body During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- Digestive comfort after dosing Scale 1-5 | During | Expected Watch
- Nasal and sinus symptoms (if allergy is the target) Scale 1-5 | During | Expected Up
Red Flags: Stop and Consult
- New or worsening autoimmune-flare symptoms (joint pain, rash, fatigue spikes); stop and consult a clinician
- Any use in phenylketonuria; spirulina contains phenylalanine and is contraindicated
- Persistent GI distress, dark urine, or jaundice, which could signal a contaminated product
Other interventions for Cardiovascular
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.480 − 0.378 = 2.102
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (2.102 / 4.00) × 5 = 7.6 / 10
Further learning
9 Best Spirulina & Chlorella Micro-Algae Supplements Review 2026
Spirulina & chlorella micro-algae are top supplements for health & longevity. But many are not safe. This review & comparison will help you pick…
ENERGYbits Algae: Best Daily Superfood
Catharine Arnston, founder of ENERGYbits, unveils the science behind spirulina and chlorella: two of the most nutrient-dense foods on the planet. Discover how these…
